Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.
Advertisement
Articles by Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
